AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2965462 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 microgram doses of hepatitis B vaccine (HB-Vax) administered intradermally at months 0 and 1, followed by two booster injections at months 5 and 10
Number of subjects: 92
Study 2965462 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 microgram doses of hepatitis B vaccine (HB-Vax) administered intradermally
Number of subjects: 92
Study 16103322 — intervention group
Group type: EXPERIMENTAL
Intervention: SPF 40 labeled as 'high protection'
Number of subjects: 367
Study 16103322 — intervention group
Group type: COMPARATOR
Intervention: SPF 40 labeled as 'basic protection'
Number of subjects: 367
Study 16103322 — intervention group
Group type: COMPARATOR
Intervention: SPF 12 labeled as 'basic protection'
Number of subjects: 367
Study 31586658 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonization
Number of subjects: 9428
Study 31586658 — intervention group
Group type: EXPERIMENTAL
Intervention: CAI
Number of subjects: 9428
Study 31586658 — intervention group
Group type: EXPERIMENTAL
Intervention: CLABSI
Number of subjects: 9428
Study 31461239 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg b.i.d.
Number of subjects: 5022
Study 31461239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5022
Study 28711577 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous SOX until progression
Number of subjects: 250
Study 28711577 — intervention group
Group type: COMPARATOR
Intervention: Stop-and-go SOX reintroduction at progression
Number of subjects: 250
Study 25239928 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site SOPT with boosters
Number of subjects: 681
Study 25239928 — intervention group
Group type: COMPARATOR
Intervention: Attention-control (crossword puzzles)
Number of subjects: 681
Study 23666451 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of naloxone 0.1 mg, droperidol 2 mg, and dexamethasone 8 mg (Cm group)
Number of subjects: 120
Study 23666451 — intervention group
Group type: COMPARATOR
Intervention: Naloxone 0.1 mg (Nx group)
Number of subjects: 120
Study 23666451 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 8 mg (Dx group)
Number of subjects: 120
Study 23666451 — intervention group
Group type: COMPARATOR
Intervention: Droperidol 1 mg (Dr group)
Number of subjects: 120
Study 21672507 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive training (CAT)
Number of subjects: 29
Study 21672507 — intervention group
Group type: COMPARATOR
Intervention: Paper-pencil cognitive training
Number of subjects: 29
Study 19468216 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor Seven for Acute Hemorrhagic Stroke (treatment group)
Number of subjects: 801
Study 19468216 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 801
Study 16624768 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical periodontal treatment combined with tetracycline
Number of subjects: 26
Study 16624768 — intervention group
Group type: COMPARATOR
Intervention: Exclusive mechanical periodontal treatment
Number of subjects: 26
Study 15470169 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose sufentanil (0.025 microg x kg(‐1) for the first patient and 0.1 microg x kg(‐1) for the other two patients)
Number of subjects: 3
Study 15470169 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.6 mg i.v.
Number of subjects: 3
Study 11168704 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation
Number of subjects: 468
Study 11168704 — intervention group
Group type: EXPERIMENTAL
Intervention: Music
Number of subjects: 468
Study 11168704 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of relaxation and music
Number of subjects: 468
Study 11168704 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 468
Study 11885079 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% xylitol mouthrinse
Number of subjects: 98
Study 11885079 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% xylitol mouthrinse
Number of subjects: 98
Study 11885079 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% xylitol mouthrinse
Number of subjects: 98
Study 11885079 — intervention group
Group type: COMPARATOR
Intervention: 1% sorbitol mouthrinse
Number of subjects: 98
Study 11885079 — intervention group
Group type: COMPARATOR
Intervention: 0.1% NaF mouthrinse
Number of subjects: 98
Study 11885079 — intervention group
Group type: COMPARATOR
Intervention: 1% xylitol mouthrinse and 0.1% NaF
Number of subjects: 98
Study 8067145 — intervention group
Group type: EXPERIMENTAL
Intervention: Two tablets containing 100,000 binding units (BU) of the toxoid and 2,500 units of O-antigen for children 11-14 years
Number of subjects: 143
Study 8067145 — intervention group
Group type: EXPERIMENTAL
Intervention: Four tablets containing 200,000 BU of the toxoid and 5,000 units of O-antigen for adolescents aged 15-17 years
Number of subjects: 143
Study 8067145 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cholera vaccine
Number of subjects: 143
Study 2942062 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 30
Study 2942062 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting nifedipine
Number of subjects: 30
Study 31377461 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete bed rest
Number of subjects: 32
Study 31377461 — intervention group
Group type: COMPARATOR
Intervention: Activity restriction
Number of subjects: 32
Study 28351962 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blocker-treated Gly49 carriers
Number of subjects: 926
Study 28351962 — intervention group
Group type: COMPARATOR
Intervention: Non-carriers and non-β-blocker-treated individuals
Number of subjects: 926
Study 28351962 — intervention group
Group type: EXPERIMENTAL
Intervention: Gly49 allele carriers in SiGN
Number of subjects: 926
Study 26755209 — intervention group
Group type: EXPERIMENTAL
Intervention: Clown therapy (interaction with clowns)
Number of subjects: 40
Study 26755209 — intervention group
Group type: COMPARATOR
Intervention: Control group (entertained by parents and ED nurses)
Number of subjects: 40
Study 25079090 — intervention group
Group type: EXPERIMENTAL
Intervention: PMTCT counselling at first visit
Number of subjects: 503
Study 25079090 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraception counselling
Number of subjects: 503
Study 25079090 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure of HIV status to partners
Number of subjects: 503
Study 25079090 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing for TB
Number of subjects: 503
Study 25079090 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose nevirapine during first ANC appointment
Number of subjects: 503
Study 22296261 — intervention group
Group type: EXPERIMENTAL
Intervention: Full integration (FI) of HIV care into antenatal care (ANC) clinics
Number of subjects: 326
Study 22296261 — intervention group
Group type: COMPARATOR
Intervention: Non-integrated (NI) model of HIV care
Number of subjects: 326
Study 19240452 — intervention group
Group type: EXPERIMENTAL
Intervention: Female faculty evaluating male residents
Number of subjects: 40
Study 19240452 — intervention group
Group type: EXPERIMENTAL
Intervention: Female faculty evaluating female residents
Number of subjects: 40
Study 19240452 — intervention group
Group type: EXPERIMENTAL
Intervention: Male faculty evaluating male residents
Number of subjects: 40
Study 19240452 — intervention group
Group type: EXPERIMENTAL
Intervention: Male faculty evaluating female residents
Number of subjects: 40
Study 19240452 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall evaluation by faculty of residents' clinical skills
Number of subjects: 40
Study 17564955 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 U of oxytocin in 30 mL of saline
Number of subjects: 79
Study 17564955 — intervention group
Group type: COMPARATOR
Intervention: 30 mL of saline
Number of subjects: 79
Study 15097300 — intervention group
Group type: EXPERIMENTAL
Intervention: ART + IL-2 (1 million IU subcutaneously once daily)
Number of subjects: 115
Study 15097300 — intervention group
Group type: COMPARATOR
Intervention: ART alone
Number of subjects: 115
Study 15097300 — intervention group
Group type: EXPERIMENTAL
Intervention: ART + IL-2
Number of subjects: 115
Study 11594571 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human interleukin‐12 (rhIL‐12)
Number of subjects: 32
Study 11594571 — intervention group
Group type: EXPERIMENTAL
Intervention: biopsy of regressing lesions
Number of subjects: 32
Study 9665682 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low calorie diet with 3.0 g fat/d
Number of subjects: 32
Study 9665682 — intervention group
Group type: COMPARATOR
Intervention: Very low calorie diet with 12.2 g fat/d
Number of subjects: 32
Study 9665682 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low calorie diet (both groups)
Number of subjects: 32
Study 9665682 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher fat meals during the first three months
Number of subjects: 32
Study 9665682 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol saturation index
Number of subjects: 32
Study 7989456 — intervention group
Group type: EXPERIMENTAL
Intervention: ISPx
Number of subjects: 30
Study 7989456 — intervention group
Group type: EXPERIMENTAL
Intervention: TSPx
Number of subjects: 30
Study 7989456 — intervention group
Group type: COMPARATOR
Intervention: Ns
Number of subjects: 30
Study 7989456 — intervention group
Group type: EXPERIMENTAL
Intervention: Kx
Number of subjects: 30
Study 7989456 — intervention group
Group type: EXPERIMENTAL
Intervention: WPx
Number of subjects: 30
Study 7989456 — intervention group
Group type: EXPERIMENTAL
Intervention: All pancreas transplanted groups
Number of subjects: 30
Study 2919093 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.3 mg/kg
Number of subjects: 0
Study 2919093 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine 0.7 mg/kg
Number of subjects: 0
Study 2919093 — intervention group
Group type: COMPARATOR
Intervention: Naloxone 1.6 mg
Number of subjects: 0
Study 4903691 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophenylbutazone
Number of subjects: 0
Study 4903691 — intervention group
Group type: COMPARATOR
Intervention: Phenylbutazone
Number of subjects: 0
Study 30700344 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 80
Study 30700344 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 80
Study 27776372 — intervention group
Group type: EXPERIMENTAL
Intervention: Drainage tube indwelled for 6 hours (Group A)
Number of subjects: 101
Study 27776372 — intervention group
Group type: EXPERIMENTAL
Intervention: Drainage tube indwelled for 12 hours (Group B)
Number of subjects: 101
Study 27776372 — intervention group
Group type: EXPERIMENTAL
Intervention: Drainage tube indwelled for 18 hours (Group C)
Number of subjects: 101
Study 27776372 — intervention group
Group type: EXPERIMENTAL
Intervention: Early removal of wound drainage tube (within 6 to 12 hours)
Number of subjects: 101
Study 26345710 — intervention group
Group type: EXPERIMENTAL
Intervention: lifestyle advice only
Number of subjects: 932
Study 26345710 — intervention group
Group type: EXPERIMENTAL
Intervention: lifestyle advice plus information on estimated 10-year CHD risk based on phenotypic characteristics
Number of subjects: 932
Study 26345710 — intervention group
Group type: EXPERIMENTAL
Intervention: lifestyle advice plus information on estimated 10-year CHD risk based on phenotypic and genetic characteristics
Number of subjects: 932
Study 26345710 — intervention group
Group type: COMPARATOR
Intervention: no intervention (control group)
Number of subjects: 932
Study 23603573 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour antenatal education session and postnatal support for fathers
Number of subjects: 699
Study 23603573 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 699
Study 23603573 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (after adjustment for age and hospital)
Number of subjects: 699
Study 23603573 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (after adjustment for socioeconomic status)
Number of subjects: 699
Study 23603573 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants of older fathers
Number of subjects: 699
Study 23603573 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants of fathers with high SES
Number of subjects: 699
Study 21324093 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic radical prostatectomy (RALRP)
Number of subjects: 128
Study 21324093 — intervention group
Group type: COMPARATOR
Intervention: Traditional laparoscopic radical prostatectomy (LRP)
Number of subjects: 128
Study 19194119 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 0.5 mg per oral (days 2 and 3)
Number of subjects: 73
Study 19194119 — intervention group
Group type: COMPARATOR
Intervention: Placebo on day 2 and granisetron 0.5 mg on days 3 and 4
Number of subjects: 73
Study 17990468 — intervention group
Group type: EXPERIMENTAL
Intervention: Bannaitong Medicinal Tea (BNT) combined with Azasetron
Number of subjects: 64
Study 17990468 — intervention group
Group type: COMPARATOR
Intervention: Azasetron alone
Number of subjects: 64
Study 15166968 — intervention group
Group type: EXPERIMENTAL
Intervention: TIPS
Number of subjects: 32
Study 15166968 — intervention group
Group type: COMPARATOR
Intervention: Peritoneovenous shunts
Number of subjects: 32
Study 15509382 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults
Number of subjects: 2
Study 15509382 — intervention group
Group type: COMPARATOR
Intervention: Children
Number of subjects: 2
Study 15509382 — intervention group
Group type: EXPERIMENTAL
Intervention: Both age groups
Number of subjects: 2
Study 10509160 — intervention group
Group type: COMPARATOR
Intervention: VEGF levels in serum (VEGFS)
Number of subjects: 0
Study 10509160 — intervention group
Group type: COMPARATOR
Intervention: VEGF levels in EDTA plasma (VEGFEDTA)
Number of subjects: 0
Study 10509160 — intervention group
Group type: COMPARATOR
Intervention: VEGF levels in platelet poor plasma (VEGFPPP)
Number of subjects: 0
Study 10509160 — intervention group
Group type: COMPARATOR
Intervention: VEGF levels in platelet rich plasma (VEGFPRP)
Number of subjects: 0
Study 10509160 — intervention group
Group type: COMPARATOR
Intervention: VEGF levels in citrated plasma (VEGFC)
Number of subjects: 0
Study 10509160 — intervention group
Group type: COMPARATOR
Intervention: PF4 levels in citrated plasma
Number of subjects: 0
Study 8520744 — intervention group
Group type: EXPERIMENTAL
Intervention: New approach (NA) mechanical ventilation
Number of subjects: 28
Study 8520744 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach (C) mechanical ventilation
Number of subjects: 28
Study 2030194 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized feedback
Number of subjects: 1217
Study 2030194 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentive
Number of subjects: 1217
Study 2030194 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1217
Study 7330436 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal encouragement
Number of subjects: 80
Study 7330436 — intervention group
Group type: COMPARATOR
Intervention: Control group (no verbal encouragement)
Number of subjects: 80
Study 29878583 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 1142524 (1-200 mg single oral doses, 5-50 mg twice daily, 100 mg once daily for 5 days)
Number of subjects: 0
Study 29878583 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 1142524 (5 mg dose)
Number of subjects: 0
Study 29878583 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 1142524 (liquid service formulation or IR tablets)
Number of subjects: 0
Study 29878583 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 1142524 (multiple dosing)
Number of subjects: 0
Study 29878583 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 1142524
Number of subjects: 0
Study 29162164 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D (25(OH)D) levels
Number of subjects: 516
Study 29162164 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum 25-hydroxyvitamin D (25(OH)D) levels
Number of subjects: 516
Study 26888558 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-apical lead position
Number of subjects: 2475
Study 24767614 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief mindfulness meditation training (3-day, 25-min per day)
Number of subjects: 66
Study 24767614 — intervention group
Group type: COMPARATOR
Intervention: Cognitive training control program
Number of subjects: 66
Study 24767614 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief mindfulness meditation training
Number of subjects: 66
Study 22679718 — intervention group
Group type: EXPERIMENTAL
Intervention: Naoxintong Capsule (NC)
Number of subjects: 240
Study 20138299 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Number of subjects: 477
Study 20138299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 477
Study 18052574 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 66
Study 18052574 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 66
Study 18052574 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 66
Study 18052574 — intervention group
Group type: COMPARATOR
Intervention: Matched healthy control group
Number of subjects: 66
Study 16124370 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenspiride (2 ml/kg/day in three divided doses)
Number of subjects: 40
Study 16124370 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (80 mg/kg/day in three partite doses) + Oxymethazolin (0.05% nasal drops 3 x day)
Number of subjects: 40
Study 12160337 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle Learning Therapy (MLT)
Number of subjects: 0
Study 12160337 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational group intervention
Number of subjects: 0
Study 12160337 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 10352334 — intervention group
Group type: EXPERIMENTAL
Intervention: Desferrioxamine (DFO) 30-40 mg/kg by slow intravenous infusion
Number of subjects: 167
Study 7588660 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthogonal technique (n = 58)
Number of subjects: 98
Study 7588660 — intervention group
Group type: COMPARATOR
Intervention: Parallel technique (n = 40)
Number of subjects: 98
Study 31088195 — intervention group
Group type: EXPERIMENTAL
Intervention: Single‐ and multiple‐dose injectable Ginkgolide B (GB)
Number of subjects: 0
Study 31088195 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg once‐daily dosing of Ginkgolide B (GB)
Number of subjects: 0
Study 31088195 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg Ginkgolide B (GB)
Number of subjects: 0
Study 31088195 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg Ginkgolide B (GB)
Number of subjects: 0
Study 31088195 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg Ginkgolide B (GB)
Number of subjects: 0
Study 31088195 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated once‐daily dosing of Ginkgolide B (GB)
Number of subjects: 0
Study 31088195 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of Ginkgolide B (GB)
Number of subjects: 0
Study 31167616 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted Percutaneous Vertebroplasty (targeted PVP)
Number of subjects: 42
Study 31167616 — intervention group
Group type: COMPARATOR
Intervention: Traditional Percutaneous Vertebroplasty (traditional PVP)
Number of subjects: 42
Study 27206964 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow oxygen therapy
Number of subjects: 22
Study 27206964 — intervention group
Group type: COMPARATOR
Intervention: Medical air (control)
Number of subjects: 22
Study 25661338 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (45mg/day)
Number of subjects: 29
Study 25661338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 25661338 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (in vitro)
Number of subjects: 29
Study 25661338 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimony treatment
Number of subjects: 29
Study 23945574 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amoxicillin
Number of subjects: 0
Study 23945574 — intervention group
Group type: COMPARATOR
Intervention: Injectable penicillin‐gentamicin combination
Number of subjects: 0
Study 21690436 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-site robotic cholecystectomy
Number of subjects: 10
Study 21690436 — intervention group
Group type: COMPARATOR
Intervention: Traditional multiport laparoscopic cholecystectomy
Number of subjects: 10
Study 19789647 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 37
Study 19789647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 16782974 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg and 6 mg (given 10 min before sedation)
Number of subjects: 98
Study 16782974 — intervention group
Group type: COMPARATOR
Intervention: Placebo (given 10 min before sedation)
Number of subjects: 98
Study 16782974 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 98
Study 16782974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 15255454 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin/mineral supplementation (36 mg vitamin E, 150 mg vitamin C, 9 mg beta-carotene) for 6 months
Number of subjects: 220
Study 15255454 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule for 6 months
Number of subjects: 220
Study 11296164 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg once daily
Number of subjects: 20
Study 11296164 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg bid
Number of subjects: 20
Study 11296164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11296164 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast and Salmeterol (after 2 weeks of treatment)
Number of subjects: 20
Study 9311490 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized lipid-extracted bovine surfactant (Alveofact) 120 mg
Number of subjects: 5
Study 9311490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 8326047 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate checkup with directive‐confrontational counseling
Number of subjects: 42